Alkahest Appoints Chief Business Officer

Alkahest, Inc. has appointed Robert Klein, Ph.D. as chief business officer. Robert Klein is a business development professional with over two decades of experience in the biotechnology, diagnostics and genomics spaces. He has spent half his career working in neuroscience drug development as both a scientist and a business development professional. 
 
Robert joins Alkahest after having served as chief business officer at Complete Genomics and having held positions of chief executive officer at iKaryos Diagnostics, chief scientific officer at Amnestix, senior director of business development at Rinat Neuroscience and then Pfizer, and vice president of business and technology development at Deltagen. 
 
"We are delighted to have Robert join our team as we approach critical milestones in the remainder of the year, including the launch of multiple additional phase 2 studies and anticipation of important clinical readouts," said Karoly Nikolich, Ph.D., chairman and chief executive officer of Alkahest. "Having spent a large part of his career as a scientist and business development professional in the neuroscience field, Robert brings with him impressive business development, M&A, and financing acumen, a broad entrepreneurial background, and a deep understanding of Alkahest’s therapeutic approach. These will prove vital as we expand our broad proteomics platform, increase our partnering efforts, and continue our clinical development programs."
 
"I could not be more excited to join the Alkahest team as the company continues to execute multiple phase 2 trials across numerous areas of great unmet need," said Dr. Klein. "The Alkahest platform focuses on the underlying biology of aging, the number one risk factor for neurodegenerative disease. By deeply studying the components of aging in human plasma, the team has identified therapeutic candidates for clinical evaluation in several devastating illnesses, an approach that I find particularly appealing both personally and professionally. I look forward to being part of a team focused on bringing these treatments to patients who otherwise have few or limited treatment options."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com